INNERVACE, INC.

Profile

Company Names

INNERVACE, INC.

Addresses

345 PARK AVENUE SOUTH, NEW YORK, NY 10010

Phone Numbers

202-352-7637

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2020

State Incorporated:

DELAWARE

Total Amount Raised:

$9,999,973.00

Number of Funding Rounds:

1
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
1
2022-08-08 
$9,999,973.00 
$40,000,000.00 
$30,000,027.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DAVID 
 
GREENWALD 
DIRECTOR
ABTECH HOLDINGS, INC.   |  ONE NYP PARTNERS I LP   |  ONE NYP PARTNERS III LP   |  ONE NYP PARTNERS QP II LP   |  INNERVACE, INC.
NADER 
 
HALIM 
EXECUTIVE OFFICER, DIRECTOR
INNERVACE, INC.
JONATHAN 
 
LEFF 
DIRECTOR
HANA BIOSCIENCES INC   |  RIB X PHARMACEUTICALS INC   |  TALON THERAPEUTICS, INC.   |  N30 PHARMACEUTICALS, INC.   |  AUDENTES THERAPEUTICS, INC.   |  AVEXIS, INC.   |  APRECIA PHARMACEUTICALS CO   |  PROTEON THERAPEUTICS INC   |  DRACEN PHARMACEUTICALS, INC.   |  ARS PHARMACEUTICALS, INC.   |  MIRUM PHARMACEUTICALS, INC.   |  CHONDRIAL THERAPEUTICS HOLDINGS, LLC   |  LARIMAR THERAPEUTICS, INC.   |  AVALYN PHARMA INC.   |  AEROVATE THERAPEUTICS, INC.   |  ADAPTIVE PHAGE THERAPEUTICS, INC.   |  INNERVACE, INC.   |  BIOMX INC.   |  ELION THERAPEUTICS, INC.   |  AXONIS THERAPEUTICS, INC.
ALTHEA 
 
STILLMAN 
EXECUTIVE OFFICER, DIRECTOR
CARISMA THERAPEUTICS INC.   |  INNERVACE, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2022-08-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-08-08 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#